A randomized, open label study of the effect of MabThera [rituximab; Rituxan] on quality of life (QOL) and treatment response in patients with rheumatoid arthritis.

Trial Profile

A randomized, open label study of the effect of MabThera [rituximab; Rituxan] on quality of life (QOL) and treatment response in patients with rheumatoid arthritis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Disease-modifying antirheumatics; Methotrexate; Rituximab
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 Planned number of patients changed from 98 to 138 as reported by Roche record.
    • 19 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top